Malignant Melanoma Recruiting Phase 2 Trials for Cobimetinib (DB05239)

Also known as: Melanoma, Malignant / [M]Malignant melanoma NOS / Melanoma / Melanoma malignant

IndicationStatusPhase
DBCOND0029825 (Malignant Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02303951Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTreatment